Ceralasertib was active as a single agent in NSCLC cell lines [116] and potentiated the cytotoxicity of cisplatin and gemcitabine in NSCLC cells, and ATM-deficient lung cancer xenografts [117]. Here, ATM is linked to non-small cell lung carcinoma.